Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gain Therapeutics (GANX) Tax Provisions (2020 - 2025)

Gain Therapeutics has reported Tax Provisions over the past 6 years, most recently at $70118.0 for Q4 2025.

  • Quarterly results put Tax Provisions at $70118.0 for Q4 2025, down 86.11% from a year ago — trailing twelve months through Dec 2025 was $861120.0 (up 60.41% YoY), and the annual figure for FY2025 was $861118.0, up 60.41%.
  • Tax Provisions for Q4 2025 was $70118.0 at Gain Therapeutics, down from $549288.0 in the prior quarter.
  • Over the last five years, Tax Provisions for GANX hit a ceiling of $549288.0 in Q3 2025 and a floor of -$8244.0 in Q4 2021.
  • Median Tax Provisions over the past 5 years was $15615.0 (2023), compared with a mean of $78709.8.
  • Biggest five-year swings in Tax Provisions: tumbled 502.63% in 2021 and later soared 11579.49% in 2025.
  • Gain Therapeutics' Tax Provisions stood at -$8244.0 in 2021, then skyrocketed by 1047.42% to $78105.0 in 2022, then plummeted by 81.43% to $14502.0 in 2023, then surged by 3380.47% to $504738.0 in 2024, then tumbled by 86.11% to $70118.0 in 2025.
  • The last three reported values for Tax Provisions were $70118.0 (Q4 2025), $549288.0 (Q3 2025), and $141205.0 (Q2 2025) per Business Quant data.